AVTX Avalo Therapeutics Inc

USD 11.72 -0.60 -4.87013
Icon

Avalo Therapeutics Inc (AVTX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 11.72

-0.60 (-4.87)%

USD 0.01B

0.01M

USD 35.00(+198.63%)

N/A

Icon

AVTX

Avalo Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 11.72
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.01B

N/A

USD 11.72

Avalo Therapeutics Inc (AVTX) Stock Forecast

Show ratings and price targets of :
USD 35.00
(+198.63%)

Based on the Avalo Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Avalo Therapeutics Inc is USD 35.00 over the next 12 months. Avalo Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Avalo Therapeutics Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Avalo Therapeutics Inc’s stock price was USD 11.72. Avalo Therapeutics Inc’s stock price has changed by -9.71% over the past week, -12.73% over the past month and -80.77% over the last year.

No recent analyst target price found for Avalo Therapeutics Inc
No recent average analyst rating found for Avalo Therapeutics Inc

Company Overview Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targ...Read More

https://www.avalotx.com

540 Gaither Road, Rockville, MD, United States, 20850

19

December

USD

USA

Adjusted Closing Price for Avalo Therapeutics Inc (AVTX)

Loading...

Unadjusted Closing Price for Avalo Therapeutics Inc (AVTX)

Loading...

Share Trading Volume for Avalo Therapeutics Inc Shares

Loading...

Compare Performance of Avalo Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AVTX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Avalo Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.48 (+0.10%) USD126.85B 31.94 20.00

ETFs Containing AVTX

Symbol Name AVTX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Avalo Therapeutics Inc (AVTX) Stock

Based on ratings from 1 analysts Avalo Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on AVTX's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for AVTX is USD 35.00 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 35.

Unfortunately we do not have enough data on AVTX's stock to indicate if its overvalued.

The last closing price of AVTX's stock was USD 11.72.

The most recent market capitalization for AVTX is USD 0.01B.

Based on targets from 1 analysts, the average taret price for AVTX is projected at USD 35.00 over the next 12 months. This means that AVTX's stock price may go up by +198.63% over the next 12 months.

We can't find any ETFs which contains Avalo Therapeutics Inc's stock.

As per our most recent records Avalo Therapeutics Inc has 19 Employees.

Avalo Therapeutics Inc's registered address is 540 Gaither Road, Rockville, MD, United States, 20850. You can get more information about it from Avalo Therapeutics Inc's website at https://www.avalotx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...